Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Roche Holdings ADR RHHBY

Healthcare
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (OTCQX:RHHBY)

Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

Business Wire 1 day ago

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

Business Wire April 18, 2024

Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Business Wire April 17, 2024

Genentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study

Business Wire April 15, 2024

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

PR Newswire April 10, 2024

Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

PR Newswire March 12, 2024

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies

Business Wire February 25, 2024

FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies

Business Wire February 16, 2024

Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics

PR Newswire February 13, 2024
View More News ››

Opinion & Analysis (OTCQX:RHHBY)

Potential Alzheimer's therapies focus on early intervention

Streetwise Reports December 1, 2017

Phase 3 trial for Inovio's VGX-3100 in cervical dysplasia gets FDA go-ahead

The Life Sciences Report June 16, 2017

Diffusion Pharmaceuticals takes aim at brain cancer: CEO David Kalergis

The Life Sciences Report April 1, 2016

BTIG's Hartaj Singh's advice for biotech investors: 'hold your powder' 'til winter

Gail Dutton October 1, 2015

Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

George S. Mack September 3, 2015

Swiss Miss: Switzerland Skirts Recession, But ETFs Struggle

Benzinga.com  August 28, 2015
View More Opinion ››

Bullboard Posts (OTCQX:RHHBY)

Novartis To Axe 680 Development Jobs Amid Global Reshuffle:

BREAKING NEWS: $RHHBF Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report | BenzingaNovartis AG@(NYSE:NVS) reportedly...
whytestocks - April 9, 2024

ONE DRUG PILL WIPES OUT COVID 19!

India's Ivermectin Blackout - Part V: The Secret Revealed ...   Sep 27, 2021 · By September 12, 2021...
zeropointenergy - October 6, 2021

Kadcyla Inventor

Took on a role at $APC.v.  $APC.v was selected for a presentation at the World Molegular Imaging Congress.  This is a...
Goldnboy1 - October 5, 2021

looking for pharma partner- amazing-

  9:33NOW PLAYING
goodheart-r - January 25, 2021

Acquires Shares of Foundation Medicine for $2.4B (EN & CH)

Not for distribution in US: Roche Acquires Remaining Shares of Foundation Medicine for $2.4 Billion Three years after acquiring a...
WesternInvestor - June 21, 2018

RE:Roche just got kicked out of IPF

Wow, and they were expecting sales of $1 Billion for that drug in 2019 !! Looks like now it could be ZERO$ by that time, as this PBI...
Bayman - April 18, 2017
View more Bullboard ››

Numinus Wellness Inc

Numinus Wellness Inc

Numinus Wellness Inc. is a Canada-based mental health care company. The Company helps people to heal and be well through the ...
View More »